Navigation Links
Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
Date:10/26/2007

ntly in a Phase 2 study as a therapy for colorectal cancer, and CPX-351, currently in a Phase 1 study for patients with leukemia, these promising results, indicating broad potential anti-tumor activity for CPX-571, represent another validation of Celator's CombiPlex technology platform," said Andrew Janoff, Ph.D., CEO of Celator.

CombiPlex(TM), Celator's proprietary technology platform, identifies the optimal ratio of drugs to use in combination therapies and then incorporates an advanced nanoparticle delivery system to maintain those optimal ratios when drugs are administered to patients.

"Based on these findings, there is significant support to advance CPX-571 to clinical development in the treatment of small cell lung cancers and potentially for use in treating other types of cancer," said Arthur Louie, M.D., Celator's chief medical officer.

ABOUT CELATOR

Celator Pharmaceuticals, Inc., is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on the optimal ratio of drug agents to target cancer cells effectively. The company pipeline includes: CPX-1, currently in a Phase 2 trial as a treatment option for colorectal cancer; CPX-351, currently in a Phase 1 trial as a treatment for leukemia (for information visit http://www.clinicaltrials.gov and search "Celator"); CPX 571, now positioned to advance to Phase 1 trial and targeting small cell lung cancer; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
4. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
5. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
6. RT-PCR Primers for the Study of Apoptosis
7. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
8. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
9. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
10. Medical College receives $377K to study brain disease
11. Kauffman study shows consistent entrepreneurial growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... UAE (PRWEB) October 22, 2014 Grace ... science and healthcare projects, announces the addition of ... DCH to its advisory team. Dr. Siddiqui will provide ... , A graduate of University College Medical ... subsequently degreed in medicine in 2001. With further certification ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
(Date:10/20/2014)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four new ... and provides a good start to Q4.  The orders are for ... and one in the Middle East . ... Peter Bruijns , President & CEO. "Total bidding activity and ... have been for any complete year since the company has tracked ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... and a better understanding of climate change are in ... University Belfast,s Institute of Electronics, Communications and Information Technology ... high performance electronic device - known as a dual ... be used in future European Space Agency (ESA) missions. ...
... Recent advances in modern manufacturing techniques,has made it ... high accuracies.,In direct response to the extreme demands ... and,position of microsystem parts, extensive research,is being carried ... micro-scale. , ,Microparts, is a joint EURAMET research ...
... ST. LOUIS, Aug. 7 KV Pharmaceutical Company (NYSE: KVa/KVb) (the ... Company,s Class A and Class B Common Stock, as further described ... purported to have been taken by such Reporting Persons on August ... By-Laws and is therefore invalid and not effective. , , ...
Cached Biology Technology:Research breakthrough will lead to more accurate weather forecasts 2KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 2KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 3KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 4KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 5KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid 6
(Date:10/16/2014)... Conn. , October 16, 2014 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... its leading edge technologies including Wocket™, the Smart Wallet, ... (FiRe) Conferenece. FiRe is a leading global conference on ... Hosted by Mark Anderson , founder and ...
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
(Date:10/14/2014)... – Like discriminating thieves, prostate cancer tumors scavenge and ... body. But such avarice may be a fatal weakness. ... way to kill prostate cancer cells by delivering a ... destroys the diseased cells brimming with the mineral, leaving ... two drugs already commercially available for other uses, could ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2
... Monkeys living on an island without big cat predators do ... played to them, according to research by a UC Davis ... hurry from the sound of human voices. "This contributes ... relaxed selection pressures," said Jessica Yorzinski, a graduate student in ...
... much more significant role in a persons ability to ... than previously understood, say scientists. Writing in Nature ... nutrients in the environment are critical to the fitness ... The findings for the first time provide a ...
... NEW YORK (Jan. 16, 2008) -- Two major federal grants ... Medical College in New York City. Dr. Kenneth ... NIH grant from the National Institute on Drug Abuse (NIDA) ... prevention program previously delivered to urban minority youth attending New ...
Cached Biology News:Diet and lifestyle critical to recovery, says study 22 federal public health grants awarded to Weill Cornell Medical College 2
... highest precision, more user-friendliness and absolute reliability ... the definition of the Mastercycler ep system. ... research has been developing dynamically. The same ... Systems. To keep pace with these ...
... is designed for easy transformation of the ... for successful transformation simply by mixing a ... cultured yeast cells. No complicated steps, such ... The kit is particularly well suited for ...
... easier. It offers a wide array of features for ... *Instruments supported: Control ... PR, SR, PG-S, PG, SG, AT, MT, UMT, AB-S, ... User guidance on the balance display ...
... powder ,Components g/500 ml: ... ,Sodium chloride 2.5 ,Agar 6.0 ... 0.250 ,IPTG 0.025 ,Kanamycin 0.0175 ... a complete growth medium containing ...
Biology Products: